Publications en collaboration avec des chercheurs de University of Edinburgh (26)

2024

  1. A genome-wide association analysis reveals new pathogenic pathways in gout*

    Nature Genetics

  2. Correction to: A genome-wide association analysis reveals new pathogenic pathways in gout (Nature Genetics, (2024), 10.1038/s41588-024-01921-5)

    Nature Genetics

2023

  1. Association of Gout Polygenic Risk Score With Age at Disease Onset and Tophaceous Disease in European and Polynesian Men With Gout

    Arthritis and Rheumatology, Vol. 75, Núm. 5, pp. 816-825

2020

  1. 2018 updated European League against Rheumatism evidence-based recommendations for the diagnosis of gout

    Annals of the Rheumatic Diseases, Vol. 79, Núm. 1, pp. 31-38

  2. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial

    The Lancet, Vol. 396, Núm. 10264, pp. 1745-1757

  3. Systematic genetic analysis of early-onset gout: ABCG2 is the only associated locus

    Rheumatology (United Kingdom), Vol. 59, Núm. 9, pp. 2544-2549

2019

  1. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 11, pp. 1592-1600

  2. Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout

    Arthritis Care and Research, Vol. 71, Núm. 3, pp. 427-434

2017

  1. 2016 updated EULAR evidence-based recommendations for the management of gout

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 1, pp. 29-42

  2. Global, regional, and national age-sex specifc mortality for 264 causes of death, 1980-2016: A systematic analysis for the Global Burden of Disease Study 2016

    The Lancet, Vol. 390, Núm. 10100, pp. 1151-1210

  3. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: A systematic analysis for the Global Burden of Disease Study 2016

    The Lancet, Vol. 390, Núm. 10100, pp. 1084-1150

2015

  1. 2015 Gout Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative

    Arthritis and Rheumatology, Vol. 67, Núm. 10, pp. 2557-2568

  2. 2015 Gout classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

    Annals of the Rheumatic Diseases, Vol. 74, Núm. 10, pp. 1789-1798

  3. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013

    The Lancet, Vol. 385, Núm. 9963, pp. 117-171

  4. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013

    The Lancet, Vol. 386, Núm. 10010, pp. 2287-2323

  5. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: Quantifying the epidemiological transition

    The Lancet, Vol. 386, Núm. 10009, pp. 2145-2191

  6. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013

    The Lancet, Vol. 386, Núm. 9995, pp. 743-800

2014

  1. Improving cardiovascular and renal outcomes in gout: What should we target?

    Nature Reviews Rheumatology, Vol. 10, Núm. 11, pp. 654-661

  2. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): A large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia

    BMJ Open, Vol. 4, Núm. 7

  3. Up-titration of allopurinol in patients with gout

    Seminars in Arthritis and Rheumatism, Vol. 44, Núm. 1, pp. 25-30